Adalimumab Biosimilar Insight Market Research | Types, Trends, Key Companies, Latest Collaborations, Licensing, Acquisition, Development, Stages Analysis and Industry Overview Report 2021 – KSU

Adalimumab Biosimilar Insight 2021 report provides comprehensive insights about 34+ companies and 35+ marketed and pipeline drugs in Adalimumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

– Global coverage

Adalimumab Understanding

Adalimumab: Overview

Adalimumab sold under the brand name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohns disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. It works by blocking a protein (tumor necrosis factor or TNF) found in the body’s immune system that causes joint swelling and damage in arthritis as well as red scaly patches in psoriasis. Adalimumab belongs to a class of drugs known as TNF blockers. By reducing joint swelling, this medication helps to reduce further joint damage and preserve joint function. After treatment with adalimumab, a decrease in levels of acute phase reactant proteins of inflammation (C reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum cytokines (IL-6) was measured compared to baseline in patients diagnosed with rheumatoid arthritis.

Adalimumab Biosimilars: Drugs Chapters

This segment of the Adalimumab report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Request a sample of Adalimumab Biosimilar Insight Market Research Report @ https://martresearch.com/contact/request-sample/2/46675                    

Adalimumab Biosimilars: Marketed Drugs

– Abrilada: Pfizer

Abrilada is an FDA-approved biosimilar version of adalimumab. Abrilada (adalimumab-afzb) injection is supplied as a sterile, preservative-free solution for subcutaneous administration. The drug product is supplied as either a single-dose prefilled pen (Abrilada pen), as a single-dose 1 mL prefilled glass syringe, or as a single-dose institutional use vial. Enclosed within the pen is a single-dose 1 mL prefilled glass syringe. Though approved, it is not yet marketed in the US like several other manufacturers of approved biosimilar versions of adalimumab, Pfizer has signed a licensing agreement with AbbVie; under the agreement, Samsung would be able to launch the drug in November 2023.

– Halimatoz: Sandoz

Halimatoz is mostly used in adults when their conditions are severe, moderately severe or getting worse, or when patients cannot use other treatments. Halimatoz contains the active substance adalimumab and is a -biosimilar medicine. The active substance in Halimatoz, adalimumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a substance in the body called tumour necrosis factor (TNF). TNF is involved in causing inflammation and is found at high levels in patients with the diseases that Halimatoz is used to treat. By attaching to TNF, adalimumab blocks its activity, thereby reducing inflammation and other symptoms of the diseases.

Further product details are provided in the report…...

Adalimumab Biosimilars: Emerging Drugs

– MYL-1401A: Mylan

MYL-1401A is an anti-TNF monoclonal antibody. This tumour necrosis factor inhibitor is a proposed biosimilar of HUMIRA (adalimumab). MYL-1401A is a recombinant human IgG1 monoclonal antibody and is being evaluated as an injectable therapy for the treatment of rheumatoid arthritis and plaque psoriasis.

– CT-P17: Celltrion

CT-P17 is the first high-concentration type of medicine for a biosimilar made of adalimumab. The company has differentiated CT-P17 from existing Humira biosimilars by halving the dosage. By taking the latest trend into account, Celltrion has also removed citrate, which can cause pain in self-injection, from its latest product. If Celltrion launches CT-P17, it will be able to complete a robust portfolio of CT-P17 in the global autoimmune disorder treatment market. CT-P17 acts as immunosuppressants and tumour necrosis factor alpha inhibitors.

Further product details are provided in the report…...

Adalimumab: Therapeutic Assessment

This segment of the report provides insights about the different Adalimumab biosimilars segregated based on following parameters that define the scope of the report, such as:

– Major  Players in Adalimumab

There are approx. 34+ key companies which are developing the therapies for Adalimumab.

– Phases

The report covers around 35+ products under different phases of clinical development like

– Marketed stage products

– Late stage products (BLA Filed and Phase III)

– Mid-stage products (Phase II and

– Early-stage products (Phase I) along with the details of

– Pre-clinical and Discovery stage candidates

– Discontinued & Inactive candidates

– Route of Administration

Adalimumab pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

– Subcutaneous

– Molecule Type

Products have been categorized under various Molecule types such as

– Monoclonal antibodies

– Peptide

— Protein

– Small molecule

– Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Adalimumab: Pipeline Development Activities

The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Adalimumab biosimilars drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adalimumab biosimilar drugs.

Browse the Full Adalimumab Biosimilar Insight Market Research Report @ https://martresearch.com/market-analysis/adalimumab-biosimilar-insight-2021/2/46675                   

Adalimumab Biosimilars Report Insights

– Adalimumab Biosimilar Pipeline Analysis

– Therapeutic Assessment

– Sales Assessment

– Unmet Needs

– Impact of Drugs

Adalimumab Biosimilar Report Assessment

– Marketed Product profiles

– Pipeline Product Profiles

– Therapeutic Assessment

– Pipeline Assessment

– Sales Assessment

– Inactive drugs assessment

– Unmet Needs

Key Players

– Zydus Cadila

– Tanvex Biopharma

– Synermore Biologics

– Shanghai Henlius Biotech

– Sandoz

– Samsung Bioepis

– Prestige BioPharma

– PlantPraxis

– Pfizer

– Outlook Therapeutics

– Mylan

– Mylan and Fujifilm Kyowa Kirin Biologics

– Mycenax Biotech

– Momenta Pharmaceuticals

– Meiji Seika Pharma

– LG Chem

– ISU Abxis

– Innovent Biologics

– HisunPharmaceuticals

– Hetero Group

– Harvest Moon Pharmaceuticals

– Gene Techno Science

– Fresenius Kabi, Germany [Bought from Merck KGaA (Merck Group)

– Epirus Biopharmaceuticals

– Daiichi Sankyo

– Coherus BioSciences

– CinnaGen

– Celltrion

– Boehringer Ingelheim

– BioXpress Therapeutics

– Bio-Thera Solutions

– Bionovis/The Instituto Vital Brazil

– Biogen

– Biocon/Mylan

– BIOCND/Genor Biopharma

– Biocad

– Amgen

– Alvotech

– mAbxience

Key Products

– Adaly

– TX17

– SYN-060

– HLX 03

– Halimatoz

– Hyrimoz

– Hadlima

– PBP 1502

– Abrilada/Amsparity

– Abrilada

– ONS-3010

– MYL-1401A

–  Hulio

– M 923

– DMB-3113

– LBAL

– ISU202

– IBI-303

– HS 016

– Pamera

– Idacio/Kromeya

– BOW 050

– CHS-1420

– Cinnora

– CT-P17

– Cyltezo

– BX 2922

– BAT-1406/Qleti

– QLETLI

– Imraldi

– MYL 1401A

– GB 232

– BCD-057

– BCD-058

– Amgevita

– Amjevita

– Solymbic

– AVT-02

– HLX03

– SB5/HADLIMA

– AMAB

– BCD 057

– GBS 005

Buy the Full Adalimumab Biosimilar Insight Market Research Report @ https://martresearch.com/paymentform/2/46675/Single_User                  

About Us:
We, at MART RESEARCH value your time the most as we believe that time saved is directly proportional to profits earned. Before launching ourselves into this service, we did an extensive survey to understand the challenges clients face while gaining access to authentic data reports. The need of the hour was a common platform which could showcase published reports across a wide range of sectors. To overcome this limitation, we setup a repository which is a comprehensive one-stop shop for all your report requirements. It is user friendly, easy to browse, search and acquire reports which would fulfill your generalized as well as customized business needs.

Contact Us:
Mart Research
5708 Copper Creek Court Charlotte North Carolina 28227, USA
+1-857-300-1122
[email protected]

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *